ClinicalTrials.gg
RecruitingNCT02579278ctDNAUpdated Oct 17, 2024

Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion

An observational study in Cancer and Rectal Cancer, sponsored by Imperial College London. Recruiting at 3 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.

Primary conditionRectal NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Rectal Neoplasms
Why
  1. The study's listed conditions name Rectal Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Started Nov 2015; still recruiting 11 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Rectal Neoplasms with a site in United Kingdom — 16 open to participants now, 26 under way, 5 of them phase 3. Rectal Neoplasms · United Kingdom.

Planned enrollment
18th of 28
100 · median 150
Started
2015
with 4 others
Observational
28 of 113
8 open now
Primary completion
2026-12
later than 12 of 25 live
Registered
71st of 113
by date
Lead sponsor
9 of 113
Imperial College London

Among the 113 studies in Rectal Neoplasms with a site in United Kingdom, this one is the 18th largest by planned enrollment of the 28 observational ones that give a count, is one of 5 that started in 2015, is one of 28 observational ones, reaches primary completion later than 12 of the 25 other live ones, and was the 71st registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

16 of the 113 studies in Rectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Rectal Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

This study does not involve randomization or treatment. Eligible patients have colorectal adenocarcinoma with no metastases eligible for curative surgery. A pre operative staging scan must have been completed within 6 weeks prior to surgery. Two x 20ml blood samples will be taken from each patient, one prior to and one during or within 24hrs after surgery. Patients are annually followed up to 3 years.

Read the detailed description

A multicentre observational study, ctDNA aims to provide the evidence base for metatstatic disease being caused by vascular methods of spread by determining if there is a link between EMVI status and ctDNA

03

Conditions studied

  • Cancer
  • Rectal Cancer

Browse trials for

Keywords

  • EMVI
  • Extramural Venous Invasion
  • mrEMVI
  • Rectal Cancer
  • ctDNA
  • Neoplasm DNA
  • MRI
04

In context

Rectal Neoplasms Reclassified

2,403 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

This study's planned enrollment of 100 is below the median of 161 across 499 observational studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Compared within Rectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

100 adult patients presenting with primary colorectal cancer proven on biopsy with no evidence of metastatic disease on CT and who are eligible for curative surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a -confirmed colorectal adenocarcinoma
  2. Is eligible for curative surgery
  3. Has no disease on CT scan
  4. Has completed pre-operative staging scan within six weeks prior to surgery
  5. Have provided written to participate in the study
  6. Be aged 16 years or over

Exclusion criteria

Exclusion Criteria:

  1. Have disease (including resectable liver metastases)
  2. Have a synchronous second
  3. Are for any imaging able to determine EMVI status
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • mrEMVI positive rectal tumours

    Patients will be registered whose rectal tumours are mrEMVI positive (i.e. EMVI is present in baseline and post-chemoradiotherapy MRI scans).

    Other: Blood sample (mrEMVI positive patient)

  • mrEMVI negative rectal tumours

    Patients registered who were mrEMVI positive at baseline MRI but have become mrEMVI negative post-chemoradiotherapy.

    Other: Blood sample (mrEMVI negative patient)

Interventions

  • OtherBlood sample (mrEMVI positive patient)

    Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.

  • OtherBlood sample (mrEMVI negative patient)

    Also known as: Two blood samples are taken from each patient with mrEMVI negative tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.

07

What researchers measure

Primary outcomes

  1. To determine if there is a link between EMVI status and ctDNA

    Proportion of patients who are EMVI positive demonstrating higher % mutation frequency of circulating cell-free and tumour specific DNA compared with patients who are EMVI negative.

    Time frame: Up to 2 years

Secondary outcomes

  1. To investigate whether ctDNA levels change during surgery according to EMVI status

    Measure the intraoperative % mutation frequency of ctDNA in EMVI positive compared with EMVI negative patients

    Time frame: Up to 2 years

  2. To investigate the effect of ctDNA status on patient survival outcomes

    Record survival outcomes of patients who are: EMVI negative with low ctDNA levels, EMVI negative with high ctDNA levels, EMVI positive with low ctDNA levels, EMVI positive with high ctDNA levels

    Time frame: At 1, 2 and 3 years

08

Study locations

3 of 3 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2015 (actual). Primary completion is estimated for Dec 2026, 133 months after the start.

Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 133 months is above that.

Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2015
First posted
Oct 19, 2015
StartActual
Nov 2015
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2029
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02579278
Responsible party
Sponsor
First posted
Oct 19, 2015
Start date
Nov 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 17, 2024

Study contacts

Caroline Martin
Contact
c.martin1@imperial.ac.uk
+44 (0) 7749 655 817
Syvella Ellis
Contact
giclinicaltrials@imperial.ac.uk
+44 (0) 7732 315 234
Gina Brown, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion